Skip to main content
Equibles
BHC logo

BHC · Bausch Health Companies Inc. · Webcasts, Transcripts & Audio

Track BHC — free

Use BHC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BHC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.44 -0.05 (-0.77%) At close · Oct 23
Rebalance outlook locked
Market Cap
$2.41B
Shares
373.99M
Volume · Oct 23 2.43M Avg daily vol (3M) 3.23M

Bausch Health Companies Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Bausch Health Companies Inc. (BHC), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q2
2026-07-29
Bausch Health Companies Inc. (BHC) Q2 2026 Earnings Call Transcript
Confident tone Quarterly financial performance Solta segment and China integration Guidance raise
Revenue
$2.85B
▲ 12.7% YoY
Diluted EPS
$0.68
▲ 70% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-05-20
Bausch Health Companies Inc. (BHC) May 20, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-29
Bausch Health Companies Inc. (BHC) Q1 2026 Earnings Call Transcript
Confident tone Revenue and EBITDA growth Salix / Xifaxan performance Tariffs
Revenue
$2.52B
▲ 11.7% YoY
Diluted EPS
$-3.82
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-18
Bausch Health Companies Inc. (BHC) Q4 2025 Earnings Call Transcript
Positive tone Revenue and EBITDA growth Solta and aesthetics growth Salix segment performance
Revenue
$2.80B*
▲ 9.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Conference
Investor event
2026-01-14
Bausch Health Companies Inc. (BHC) January 14, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q3
2025-10-29
Bausch Health Companies Inc. (BHC) Q3 2025 Earnings Call Transcript
Confident tone Raised full-year guidance Salix / Xifaxan performance Solta Medical growth and APAC dependency
Revenue
$2.68B
▲ 6.8% YoY
Diluted EPS
$0.48
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript
Positive tone Revenue and Adjusted EBITDA Growth Salix / Xifaxan Performance Solta and International Growth
Revenue
$2.53B
▲ 5.3% YoY
Diluted EPS
$0.40
▲ 1233.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-30
Bausch Health Companies Inc. (BHC) Q1 2025 Earnings Call Transcript
Confident tone Revenue and EBITDA growth Solta international growth Xifaxan / Salix performance
Revenue
$2.26B
▲ 4.9% YoY
Diluted EPS
$-0.16
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-19
Bausch Health Companies Inc. (BHC) Q4 2024 Earnings Call Transcript
Confident tone Revenue and EBITDA growth Bausch + Lomb (BLCO) monetization IRA price negotiation for Xifaxan
Revenue
$2.56B*
▲ 6.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Bausch Health Companies Inc. (BHC) Q3 2024 Earnings Call Transcript
Confident tone Quarterly financial performance and guidance raise XIFAXAN growth and lifecycle management Solta medical aesthetics growth
Revenue
$2.51B
▲ 12.2% YoY
Diluted EPS
$-0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Bausch Health Companies Inc. (BHC) Q2 2024 Earnings Call Transcript
Positive tone Xifaxan Franchise and IP Defense Bausch + Lomb Separation Solta Aesthetics Growth
Revenue
$2.40B
▲ 10.9% YoY
Diluted EPS
$0.03
▼ 57.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Bausch Health Companies Inc. (BHC) Q1 2024 Earnings Call Transcript
Positive tone Quarterly Revenue and EBITDA Growth Xifaxan IP and Litigation IRS / Granite Trust Settlement
Revenue
$2.15B
▲ 10.8% YoY
Diluted EPS
$-0.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Bausch Health Companies Inc. (BHC) Q4 2023 Earnings Call Transcript
Positive tone 2023 Results and 2024 Guidance R&D Pipeline (Amiselimod, RED-C) Salix Segment / Xifaxan Franchise
Revenue
$2.41B*
▲ 9.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Bausch Health Companies Inc. (BHC) Q3 2023 Earnings Call Transcript
Revenue
$2.24B
▲ 9.4% YoY
Diluted EPS
$-1.03
▼ 193.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Bausch Health Companies Inc. (BHC) Q2 2023 Earnings Call Transcript
Revenue
$2.17B
▲ 10.2% YoY
Diluted EPS
$0.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Bausch Health Companies Inc. (BHC) Q1 2023 Earnings Call Transcript
Revenue
$1.94B
▲ 1.4% YoY
Diluted EPS
$-0.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Bausch Health Companies Inc. (BHC) Q4 2022 Earnings Call Transcript
Revenue
$2.19B*
▼ 0.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Bausch Health Companies Inc. (BHC) Q3 2022 Earnings Call Transcript
Revenue
$2.05B
▼ 3.1% YoY
Diluted EPS
$1.10
▲ 111.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Bausch Health Companies Inc. (BHC) Q2 2022 Earnings Call Transcript
Revenue
$1.97B
▼ 6.3% YoY
Diluted EPS
$-0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-04-28
Bausch Health Companies Inc. (BHC) Q1 2022 Earnings Call Transcript
Revenue
$1.92B
▼ 5.4% YoY
Diluted EPS
$-0.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Bausch Health Companies Inc. (BHC) Q4 2021 Earnings Call
Revenue
$2.20B*
▼ 0.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Bausch Health Companies Inc. (BHC) Q3 2021 Earnings Call
Revenue
$2.11B
▼ 1.3% YoY
Diluted EPS
$0.52
▲ 160% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Bausch Health Companies Inc. (BHC) Q2 2021 Earnings Call
Revenue
$2.10B
▲ 26.2% YoY
Diluted EPS
$-1.66
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Bausch Health Companies Inc. (BHC) Q1 2021 Earnings Call
Revenue
$2.03B
▲ 0.7% YoY
Diluted EPS
$-1.71
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-13
Bausch Health Companies Inc. (BHC) Q4 2020 Earnings Call Transcript
Revenue
$2.21B
▼ 0.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-03
Bausch Health Companies Inc. (BHC) Q3 2020 Earnings Call Transcript
Revenue
$2.14B
▼ 3.2% YoY
Diluted EPS
$0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Bausch Health Companies Inc. (BHC) Q2 2020 Earnings Call Transcript
Revenue
$1.66B
▼ 22.7% YoY
Diluted EPS
$-0.92
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Bausch Health Companies Inc. (BHC) Q1 2020 Earnings Call Transcript
Revenue
$2.01B
▼ 0.2% YoY
Diluted EPS
$-0.43
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–28 of 28 webcasts
Key facts CIK 885590 CUSIP 071734107 13F (30d) 30 filings 27 filers Visit website Investor relations